Treatment with denosumab vs oral bisphosphonates was associated with increased risks for MACE and hypocalcemia in dialysis-dependent patients with osteoporosis.
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030. The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback